Alexandria

Senda Biosciences is pioneering the field of Intersystems Biology to create novel treatments for human disease. Intersystems Biology focuses on how molecular connections between botanical, bacterial, and human cells—coevolved over millennia—define health and disease. Senda's Intersytems Biology discovery platform, built using new techniques in machine learning and computational biology, has been able to generate novel, actionable insights into the trillions of interspecies molecular connections in the human body, and harnesses the power of this "pharmacy within us" with novel pharmacological approaches. The power of the Senda platform is illustrated by six preclinical programs in oncology, neurology, chronic disease, and metabolic disease.

Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Element Biosciences, Inc. develops genetic analysis tools for the research and diagnostic markets. The company provides a disruptive DNA sequencing technology and a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. The company was incorporated in 2017 and is based in San Diego, California.

GreenLight Biosciences is a biotechnology company that specializes in RNA-based solutions for agricultural and pharmaceutical applications. Founded in 2008 and headquartered in Medford, Massachusetts, with an additional location in North Carolina, the company utilizes its Unconstrained Metabolism technology platform to convert renewable substrates into valuable chemicals and fuels. This platform allows for significant flexibility and control in the production process. GreenLight is also focused on developing RNA products aimed at improving crop management, plant protection, and animal health, while advancing vaccine development and pandemic preparedness. In addition to these applications, the company is working on mRNA-based vaccine candidates targeting seasonal and pandemic influenza, as well as other emerging viruses, to enhance public health. Through its innovations, GreenLight aims to provide sustainable solutions that contribute to global food security and health.

Biodesy has developed a unique and highly sensitive means of detecting conformational change in proteins and other biological molecules. Our technology, based on a phenomenon called ‘second-harmonic generation’ (SHG), can monitor structural change at any site within a protein, in real time.

LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s full-stack platform vertically integrates proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. By providing both commercial and academic researchers and therapeutic developers with unprecedented access to cutting-edge genome engineering, Synthego is at the forefront of innovation, accelerating the development of truly engineered biology. The company was founded in 2012 and is based in Redwood City, California.